Differences in immune responses due to age, sex, and genetics

Over the course of our life, we are continuously exposed to pathogens such as viruses and bacteria, meaning that our immune system is constantly at work. When stimulated by either pathogen or vaccine, the immune system notably mounts what is known as a "humoral response", which corresponds to the production of antibodies that can help fight infections and provide long-term protection.

The intensity of humoral responses differs from person to person. Understanding why, and identifying the specific determinants of this variability could help us improve vaccines, predict a person's susceptibility to a particular pathogen, or get a deeper understanding of autoimmune diseases.

In a new study published in Genome Medicine, the lab of Jacques Fellay at EPFL, working with the Pasteur Institute in Paris, have examined the humoral responses of 1,000 healthy people to common infections and vaccines. The scientists measured antibody responses to fifteen antigens (molecules that trigger humoral responses) from twelve infectious agents: cytomegalovirus, Epstein-Barr virus, herpes simplex virus 1 and 2, varicella zoster virus, influenza A virus, measles, mumps, rubella, and hepatitis B virus, Helicobacter pylori and Toxoplasma gondii.

In order to assess the importance of non-genetic factors, the researchers looked at the impact of numerous demographic variables. They identified age and sex as the most important determinants of humoral response, with older individuals and women showing stronger antibody responses against most antigens.

For the genetic factors, the scientists performed genome-wide association studies, which allow the exploration of the potential impact of genetic variation throughout the human genome. The studies showed that differences in response to Epstein-Barr virus and rubella associate with variation in the human leucocyte antigen (HLA) gene region, which encodes proteins involved in the recognition of foreign antigens.

"To combat infectious and autoimmune diseases, we need to better understand variation in the healthy immune response", says Jacques Fellay. "Our study is a necessary first step toward individualized healthcare in infection and immunity".

Petar Scepanovic, Cécile Alanio, Christian Hammer, Flavia Hodel, Jacob Bergstedt, Etienne Patin, Christian W Thorball, Nimisha Chaturvedi, Bruno Charbit, Laurent Abel, Lluis Quintana-Murci, Darragh Duffy, Matthew L Albert, Jacques Fellay, The Milieu Intérieur Consortium.
Human genetic variants and age are the strongest predictors of humoral immune responses to common pathogens and vaccines.
Genome Medicine201810:59. doi: 10.1186/s13073-018-0568-8.

Most Popular Now

Novartis receives FDA approval for Mayzent® (sipon…

Novartis today announced that the US Food and Drug Administration (FDA) has approved Mayzent® (siponimod) for the treatment of adults with relapsing forms of multiple scl...

Compound that kills drug-resistant fungi is isolat…

Antimicrobial and antifungal resistance, which describe the ability of bacteria and other pathogens to resist the effects of drugs to which they were once sensitive, is a...

First bacterial genome created entirely with a com…

All the genome sequences of organisms known throughout the world are stored in a database belonging to the National Center for Biotechnology Information in the United Sta...

Liver, colon cancer cells thwarted by compounds de…

The plant that adds flavor, color and bitterness to beer also produces a primary compound that thwarts cancer cells, and two important derivatives of the compound do as w...

Clinical trial finds therapy to be well-tolerated …

A phase I clinical trial that set out to assess the safety of a new combination therapy for a type of aggressive brain tumour has found the treatment to be well tolerated...

Immune cells fighting blood cancer visualized for …

When cancer escapes the immune system, our defenses are rendered powerless and are unable to fight against the disease. Chimeric antigen receptor T cells (CAR T cells) re...

FDA approves treatment for patients with a type of…

The U.S. Food and Drug Administration today approved Cimzia (certolizumab pegol) injection for treatment of adults with a certain type of inflammatory arthritis called no...

Boehringer Ingelheim announces FDA and EMA regulat…

Boehringer Ingelheim has filed for regulatory approval of nintedanib in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD) with the FDA and E...

Selumetinib granted US Breakthrough Therapy Design…

AstraZeneca and MSD, Inc., Kenilworth, NJ, US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that the US Food and Drug Administration (FDA) ha...

Novartis adds clinical and preclinical anti-inflam…

Novartis announced that it is adding to its broad portfolio of immunomodulatory medicines with the planned acquisition of IFM Tre, a subsidiary of IFM Therapeutics LLC fo...

Forxiga approved in Japan for type-1 diabetes

The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Forxiga (dapagliflozin) as an oral adjunct treatment to insulin for adults with type-1 diabetes (T...

Novartis continues transformation into a leading m…

Novartis today completed the spin-off of the Alcon eye care devices business through a dividend-in-kind distribution to holders of Novartis shares and ADRs (American Depo...